July 20, 2020: India's first coronavirus vaccine COVAXIN human trials are beginning today at the All India Institute of Medical Science (AIIMS), Delhi after its Ethics Committee gave its nod.
COVAXIN is an indigenously developed COVID-19 vaccine candidate following which country's premier hospital is all set to begin the exercise by enrolling healthy volunteers from Monday.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin.
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomized, double-blind, placebo-controlled clinical trial.
Few volunteers have already registered for the trial.
AIIMS will start the screening of the individuals and evaluate their health condition from Monday (today) onwards before vaccinating them.
COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
Noting that this was the first indigenous vaccine being developed by India, ICMR Director General Dr Balram Bhargava in a letter to principal investigators of the 12 sites recently had asked them to fast-track the human clinical trial an approval stating it is one of the "top priority projects which is being monitored at the top-most level of the government".
The trials have so far started in AIIMS, Patna and some more sites.
STORY HIGHLIGHTS
July 20, 2020: India's first coronavirus vaccine COVAXIN human trials are beginning today at the All India Institute of Medical Science (AIIMS), Delhi after its Ethics Committee gave its nod.
July 20, 2020: India's first coronavirus vaccine COVAXIN human trials are beginning today at the All India Institute of Medical Science (AIIMS), Delhi after its Ethics Committee gave its nod.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin.
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomized, double-blind, placebo-controlled clinical trial.
Few volunteers have already registered for the trial.
AIIMS will start the screening of the individuals and evaluate their health condition from Monday (today) onwards before vaccinating them.
COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
Noting that this was the first indigenous vaccine being developed by India, ICMR Director General Dr Balram Bhargava in a letter to principal investigators of the 12 sites recently had asked them to fast-track the human clinical trial an approval stating it is one of the "top priority projects which is being monitored at the top-most level of the government".
The trials have so far started in AIIMS, Patna and some more sites.